Insulin Hypersecretion

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2009-09-22
Clinical Trial Update: Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity [Phase 2]
A Phase 2 clinical trial of Sandostatin LAR Depot in patients with primary insulin hypersecretion and obesity has completed. No results are …